Do tedizolid have bone penetration?
Reading File
Finding Sources
Searching PubMed
tedizolid bone penetration pharmacokinetics
Reading File
Searching PubMed
tedizolid tissue distribution bone
Searching the Web
tedizolid bone penetration ratio pharmacokinetics osteomyelitis
I now have a thorough picture. Here is a synthesized answer:
Tedizolid and Bone Penetration
Short answer: Tedizolid has good soft-tissue penetration but bone-specific penetration data is limited and somewhat uncertain compared to its muscle/lung/adipose data.
What we know from pharmacokinetics
Tedizolid phosphate is a second-generation oxazolidinone prodrug that is hydrolyzed to the active moiety tedizolid. Key PK facts:
- Oral bioavailability: 91%
- Half-life: ~12 hours (allows once-daily dosing at 200 mg)
- Protein binding: 70-90% (higher than linezolid's 31%)
- Plasma concentrations are considered a good surrogate for tissue concentrations because it penetrates well into muscle, adipose, and pulmonary tissues - (Katzung's Basic and Clinical Pharmacology, 16th ed.)
Specific tissue penetration ratios (free AUC tissue/free AUC plasma)
| Tissue | Penetration ratio |
|---|---|
| Muscle | ~1.2 |
| Adipose tissue | ~1.1 |
| Epithelial lining fluid (ELF) | ~40x plasma |
| Alveolar macrophages | ~20x plasma |
| Synovial fluid | ~88-130% of plasma |
| Bone (cortical/cancellous) | Limited direct data |
The synovial fluid ratio of 88-130% is particularly encouraging for joint infections. Bone-specific penetration has not been as well characterized as for linezolid.
Evidence for bone/joint infections
While formal bone penetration studies are limited, there are promising signals:
-
In vitro activity: A large surveillance study (2015-2019) confirmed potent activity of tedizolid against gram-positive pathogens causing bone and joint infections, including MRSA and coagulase-negative staphylococci (Antimicrobial Agents and Chemotherapy).
-
Foreign-body osteomyelitis model: A 2016 experimental study (PMID: 27550347) evaluated tedizolid in a murine MRSA foreign body-associated osteomyelitis model and showed activity.
-
Clinical case series: A 2025 systematic review evaluated published evidence for tedizolid in osteoarticular infections (prosthetic joint infections, osteomyelitis, septic arthritis) and reported off-label use with clinical success, though data remain limited.
-
A prospective cohort of 44 patients with bone and joint infections (osteomyelitis, prosthetic joint infections, hardware-associated infections) treated with 4-12 weeks of tedizolid found no cases of cytopenias or neuropathy - a major safety advantage over linezolid for prolonged courses.
Comparison with linezolid (bone penetration)
| Feature | Linezolid | Tedizolid |
|---|---|---|
| Bone:plasma ratio | 0.2-0.6 (documented) | Not well defined |
| Bone concentration | 4-9 mcg/mL | Inferred from plasma |
| Synovial fluid penetration | Good | 88-130% of plasma |
| Formal bone PK studies | Yes | Limited |
Bottom line
Tedizolid is expected to have clinically relevant bone penetration based on its excellent tissue distribution properties and high plasma-to-tissue correlation. However, formal cortical/cancellous bone concentration studies in humans are lacking. The current evidence for its use in osteomyelitis and prosthetic joint infections is based on case series and animal models rather than dedicated bone PK trials. The European Review for Medical and Pharmacological Sciences states: "Current evidence is not sufficient to support its [tedizolid's] use in the treatment of osteomyelitis, lacking data on its bone penetration."
That said, its once-daily dosing, lower risk of bone marrow suppression with prolonged use, and good tissue penetration make it an appealing agent for bone infections where linezolid-class therapy is needed but linezolid toxicity is a concern.
This is a shared conversation. Sign in to Orris to start your own chat.